Drug intelligence / Profile preview

IDOV-Immune

Development stage: Phase 2
Lead developer: ViroMissile
Modality: Oncolytic Viruses → Oncolytic Therapeutics, Recombinant Proteins and Enzymes
Administration: Intratumoral, Intravenous

Overview

IDOV-Immune is a genetically engineered oncolytic vaccinia virus developed to selectively infect and destroy tumor cells while enhancing anti-tumor immune responses. The drug is designed to improve therapeutic efficacy by stimulating the immune system against cancer, particularly in patients with advanced solid tumors such as microsatellite stable (MSS) colorectal cancer. Its mechanism involves direct tumor cell lysis and the induction of systemic anti-tumor immunity, making it part of a new generation of oncolytic viral therapies that aim to convert immunologically "cold" tumors into "hot" ones, thereby promoting long-lasting immunological memory against cancer recurrence[1][3][5]. The developer is ViroMissile.

Other names: Oncolytic Virus injection

Beyond the preview

Go deeper on IDOV-Immune.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDOV-Immune.